Nemaura Medical to offer CGM-guided insulin dose titration care model

Nemaura Medical has announced that it now includes insulin under its DuoPack commercial license agreement.

Nemaura Medical entered into a commercial agreement in September 2021 with MySugarWatch DuoPack Limited (MSWDL), under which Nemaura’s non-invasive, wearable skin patch sensors are paired with prescription-only medicines for Type 2 diabetes. This combination of sensors and medicine aims to provide a ‘one-stop shop’ supported by a holistic care approach.

The inclusion of insulin in our agreement with MSWDL means patients with type 2 diabetes will have access to a CGM-guided insulin dose titration care model that is designed to reduce hypoglycemic episodes and hospital admissions while improving long-term outcomes,” said Nemaura CEO Dr. Faz Chowdhury. “Moreover, it uniquely avoids a potentially bruised, slow-to-heal, infection-prone, needle-induced skin puncture wound in older patients at the site of a CGM sensor skin application.”

To read more, CLICK HERE.

Desang Diabetes Magazine is our free-to-receive digital journal (see below). We cover diabetes news, diabetes management equipment (diabetes ‘kit’ such as insulin pumps and continuous glucose monitoring equipment) and news about food suitable for a diabetic diet including a regular Making Carbs Count column. We just need your email address to subscribe you (it really is free, and you can easily unsubscribe should you wish to).

Sign me up!
Open publication
Buy a Desang kitbag

See our range of kitbags